NCT03894501

Brief Summary

This pilot study aims to evaluate the impact of a novel intervention, Mindfulness Oriented Recovery Enhancement (MORE), on opioid use and chronic pain among individuals receiving methadone maintenance treatment (MMT). The main goal of this pilot study is to test the feasibility of our study methods before conducting a clinical trial to assess MORE with respect to a range of clinical outcomes. This study will involve a 2-arm individually randomized controlled trial design that compares MORE and treatment as usual (TAU).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 31, 2019

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 26, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 28, 2019

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 19, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 19, 2019

Completed
2.6 years until next milestone

Results Posted

Study results publicly available

January 11, 2022

Completed
Last Updated

January 11, 2022

Status Verified

November 1, 2021

Enrollment Period

5 months

First QC Date

March 26, 2019

Results QC Date

May 19, 2021

Last Update Submit

November 9, 2021

Conditions

Keywords

opioidchronic painmethadonemindfulness

Outcome Measures

Primary Outcomes (15)

  • Study Interest

    The number of individuals who express interest in the study.

    Baseline

  • Study Refusal

    The number of individuals who who refuse participation when offered.

    Baseline

  • Individuals Screened

    The number of individuals screened and eligible/ineligible.

    Baseline (study enrollment)

  • Individuals Consented.

    The number of individuals consented.

    Baseline (study enrollment)

  • Refusal After/During Consent Process.

    The number of individuals who refuse participation after/during consent process.

    Enrollment

  • Mean Sessions Completed

    The mean number of sessions completed by study participants in the MORE intervention.

    At 8-weeks (post treatment period completion).

  • Percentage of Sessions Completed

    The mean percentage of sessions completed by study participants randomized to MORE.

    At 8-weeks (post treatment period completion).

  • Number Who Drop Out

    Number of participants who drop out of the study.

    At 16 weeks.

  • Percentage Who Drop Out

    Percentage of participants who drop out of the study.

    At 16 weeks.

  • Baselines Completed

    The number of participants who complete baseline assessments.

    At baseline,

  • Percentage Baselines Completed

    Percentage of people who completed baseline assessments.

    At baseline,

  • 8-weeks Completed

    The number of participants who complete 8-week assessments.

    At 8-weeks.

  • Percentage 8-Weeks Completed

    Percentage of participants who completed 8-week assessments.

    At 8-weeks.

  • 16-Weeks Completed

    The number of participants who completed 16-week assessments.

    At 16-weeks.

  • Percentage of 16-Weeks Completed

    Percentage of participants who completed 16-week assessments.

    At 16-weeks.

Secondary Outcomes (6)

  • Days of Illicit Drug Use

    16-weeks

  • Days of Illicit Opioid Use

    16-weeks

  • Opioid Craving

    16-weeks

  • Pain Level.

    16-weeks

  • Depression Level.

    16-weeks

  • +1 more secondary outcomes

Study Arms (2)

Mindfulness Oriented Recovery Enhancement

EXPERIMENTAL

The Mindfulness Oriented Recovery Enhancement arm will participate in eight, weekly, two-hour group sessions.MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.

Behavioral: Mindfulness Oriented Recovery Enhancement

Methadone program behavioral treatment as usual

OTHER

In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.

Behavioral: Methadone program behavioral treatment as usual

Interventions

MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.

Also known as: MORE
Mindfulness Oriented Recovery Enhancement

In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.

Also known as: Treatment as Usual, TAU
Methadone program behavioral treatment as usual

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 or older
  • English-speaking
  • Been in methadone treatment for at least 3 months
  • Experience a non-malignant pain (with an intensity level of 8 or higher on the Gracely Box Scale) for a duration of 2 months or longer.

You may not qualify if:

  • Exhibit cognitive impairment (score \<24 on the Mini Mental Status Exam)
  • Exhibit psychosis (positive SCID Psychotic Screen),
  • Are at suicidal risk (positive score on ASQ Suicide Risk Screening Tool)
  • Unable to attend group sessions due to distance, work, commitments or other logistical problems,
  • Are currently pregnant or breastfeeding
  • Are planning to be pregnant or breastfeeding the next 16 weeks.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rutgers Robert Wood Johnson Medical School

New Brunswick, New Jersey, 08901, United States

Location

Related Publications (1)

  • Garland EL, Hanley AW, Kline A, Cooperman NA. Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: Ecological momentary assessments from a stage 1 randomized controlled trial. Drug Alcohol Depend. 2019 Oct 1;203:61-65. doi: 10.1016/j.drugalcdep.2019.07.007. Epub 2019 Aug 5.

MeSH Terms

Conditions

Chronic Pain

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Nina Cooperman
Organization
Rutgers Robert Wood Johnson Medical School

Study Officials

  • Nina A Cooperman, PsyD

    Rutgers Robert Wood Johnson Medical School

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Two-arm randomized controlled trial.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

March 26, 2019

First Posted

March 28, 2019

Study Start

January 31, 2019

Primary Completion

June 19, 2019

Study Completion

June 19, 2019

Last Updated

January 11, 2022

Results First Posted

January 11, 2022

Record last verified: 2021-11

Data Sharing

IPD Sharing
Will share

Analyses of data generated from this project will be shared with the scientific community through publications in peer-reviewed journals and presentations at scientific meetings. The proposed research will include data from approximately 30 individuals in methadone maintenance treatment. The final dataset will include self-reported demographic and behavioral data from interviews with the subjects and laboratory data from urine specimens provided. Because we will be following study participants, we will be collecting identifying information. The final dataset will be stripped of identifiers prior to release for sharing.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
Beginning 3 months and ending 36 months after study publication.
Access Criteria
We will make the data and associated documentation available to research community scientists only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.

Locations